Precision Financing of Durable, Potentially Curative Therapies

Eric NormanArticles, FoCUS

Pharmaceutical Executive, January 27, 2019

Trusheim, Jane Barlow Russell Teagarden Mark

Gene therapies and cellular treatments create multiple financial challenges for US healthcare payers beyond price. The work of the multi-stakeholder Financing and reimbursement of Cures in the US (FoCUS) consortium suggests that payer type affects the manner and severity of these challenges, which in turn makes a single financial solution unlikely. Rather, FoCUS participants suggest that US payers require a precision financing toolset customizable for each payer’s needs, for each durable therapy’s characteristics and in the context of the growing portfolio of such treatments.

Read the article